Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series.

Andrew G WeberAlice S ChauMikala EgebladBetsy J BarnesTobias Janowitz

Published in: Molecular medicine (Cambridge, Mass.) (2020)

Results suggest that dornase alfa will be well-tolerated by patients with severe COVID-19. Clinical trials are required to formally test the dosing, safety, and efficacy of dornase alfa in COVID-19, and several have been recently registered.

Keyphrases

sars cov
coronavirus disease
replacement therapy
clinical trial
intensive care unit
respiratory syndrome coronavirus
early onset
acute respiratory distress syndrome
smoking cessation
randomized controlled trial